Healthcare Services

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Expected to Reach $32.86 Billion by 2030 with 16.2% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market During 2026–2030?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market has seen significant expansion in recent times. Its value is projected to increase from $15.5 billion in 2025 to $18.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.3%. Factors contributing to its historical growth include a rise in obesity prevalence, innovations in diabetes medications, the increasing burden of lifestyle diseases, the early adoption of glp-1 for diabetes treatment, and various healthcare awareness campaigns.

The glucagon-like peptide (glp)-1 agonists weight loss drugs market is set for significant expansion over the next few years, with projections indicating it will reach $32.87 billion in 2030, expanding at a compound annual growth rate (CAGR) of 16.2%. The anticipated growth during the forecast period is primarily driven by the approval of new glp-1 drugs, the expansion of obesity clinics, increased insurance coverage, a growing focus on long-term weight management, and rising global obesity rates. Prominent trends for this period include a surging demand for pharmacological weight management solutions, the increased use of injectable weight loss drugs, the growing adoption of glp-1 therapies beyond diabetes, the expansion of obesity treatment programs, and improved patient adherence to long-term therapy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp

What Underlying Factors Are Accelerating The Growth Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The increasing occurrence of obesity is projected to boost the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market in the future. Obesity is defined as a medical state where excessive body fat accumulates, posing health risks. The rates of obesity are climbing, attributed to poor dietary practices, including higher consumption of fast food and sugary beverages, which lack essential nutrients and balance. With the growing count of people impacted by obesity and associated health issues, the need for efficacious treatment choices is escalating, consequently fostering the adoption of glucagon-like peptide (GLP)-1 agonist weight loss drugs due to their established effectiveness in promoting weight loss and improving metabolic well-being. For example, data from May 2025, provided by the Office for Health Improvement and Disparities, a UK-based government body, indicated that from 2023 to 2024, approximately 64.5% of adults aged 18 and over in England were classified as overweight or living with obesity, marking an increase from 64.0% recorded between 2022 to 2023. Consequently, the expanding prevalence of obesity is fueling the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market.

How Are The Various Segments Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Categorized?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market covered in this report is segmented –

1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs

2) By Route of Administration: Parenteral, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies

Subsegments:

1) By Semaglutide: Ozempic, Wegovy, Rybelsus

2) By Liraglutide: Saxenda, Victoza

3) By Tirzepatide: Mounjaro, Zepbound

4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide

What Key Trends Are Influencing The Development Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Leading companies active in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing innovative solutions for obesity treatment, aiming to boost efficacy and improve patient outcomes. These obesity treatment solutions are therapies that mimic the GLP-1 hormone to help regulate appetite, enhance satiety, and promote weight loss. Such drugs contribute to managing obesity by improving metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, gained US Food and Drug Administration approval for Zepbound, a medication designed for chronic weight management in adults who are obese or overweight with related health conditions such as type 2 diabetes or sleep apnea. This drug functions by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.

Which Major Firms Influence Developments In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd

Read the full glucagon-like peptide (glp)-1 agonists weight loss drugs market report here:

https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-glp-1-agonists-weight-loss-drugs-global-market-report

Which Region Is Projected To Dominate The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market During The Forecast Period?

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2025. The regions covered in the glucagon-like peptide (glp)-1 agonists weight loss drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp

Browse Through More Reports Similar to the Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market 2026, By The Business Research Company

Kidney Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Chronic Kidney Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Diabetic Kidney Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info